| Assessment Status |
Awaiting response from Applicant |
| HTA ID |
22024 |
| Drug |
Enfortumab vedotin |
| Brand |
Padcev® |
| Indication |
As monotherapy for the treatment of adult patients with locally advanced or metastatic urothelial cancer (la/mUC) who have previously received a platinum-containing chemotherapy and a programmed death receptor-1 or programmed death-ligand 1 inhibitor |
| Rapid review commissioned |
22/04/2022 |
| Rapid review completed |
18/05/2022 |
| Rapid review outcome |
A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of enfortumab vedotin (Padcev®) compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE |
27/05/2022 |
| Pre-submission consultation with Applicant |
19/07/2022 |
| Full submission received from Applicant |
23/11/2022 |
| Preliminary review sent to Applicant |
16/03/2023 |
